. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: J Am Soc Hypertens. 2015 Jun 5;9(8):592–599. doi: 10.1016/j.jash.2015.05.014

Table 4.

The association between hypertension and FOP, F₂-isoP, MtDNA, γ-Toc, and OBS

Marker	Method 1	Method 2
Marker	AOR	AOR
FOP
Low	Ref	Ref
High	2.11 (0.88–5.06)	1.69 (0.92–2.53)
FOP (continuous, per 1-SD)	1.49 (0.89–2.51)	1.58 (0.96–2.20)
F₂-isoP
Low	Ref	Ref
High	0.75 (0.27–2.06)	0.74 (0.35–1.55)
F₂-isoP (continuous, per 1-SD)	0.94 (0.53–1.67)	0.99 (0.98–1.01)
MtDNA
Low	Ref	Ref
High	1.86 (0.62–5.63)	1.13 (0.75–1.71)
MtDNA (continuous, per 1-SD	0.94 (0.53–1.65)	1.04 (0.67–1.61)
γ-Toc
Low	Ref	Ref
High	1.20 (0.51–2.82)	1.03 (0.67–1.58)
γ-Toc (continuous, per 1-SD)	0.93 (0.60–1.43)	0.32 (0.01–21.60)
OBS
Low (2–8)	Ref	Ref
Medium (9–14)	0.30 (0.13–0.72)	0.89 (0.53–1.49)
High (15–22)	0.17 (0.03–0.95)	0.56 (0.22–1.43)
Continuous	0.87 (0.79–0.96)	0.91 (0.84–0.99)

AOR, adjusted odds ratio, controlling for age, sex, race or origin, education (smoking, aspirin use, and BMI) (when predictor was not OBS)—each biomarker was dichotomized based on sex and race- or origin-specific median; BMI, body mass index; continuous, per 1-SD, continuous variable scaled to 1 standard deviation; F₂-isoP, F₂-isoprostanes; FOP, fluorescent oxidative products; γ-Toc, gamma tocopherol; Method 1, original data used pairwise deletion; Method 2, used multiple imputation to handle missing data; MtDNA, mitochondrial DNA copy number.